Stock Analysis of Angion Biomedica Corp (ANGN) - Birds Eye View

1W   2W   1M   3M   1Y   2Y   5Y   
Overview
Code ANGN
Close 1.00
Change 0.0200 / 2.04 %
Volume 224843
Vol Change -88896.00 / 28.33 %
IndustryBiotechnology
SectorHealthcare
AIO Strength Index
Technical StrengthStrong Bullish
Growth Index Very Low Growth Stock
Value Index Low Value Stock
Profitability Index Poor Profitability Stock
Stability Index Low Stability Stock


Fundamental View of Angion Biomedica Corp
PE (TTM)

-1.04

Very Poor
Price / Book

0.577

Very Good
Price / Sales

10.18

Very Poor
Piotroski F Score

2.0

Poor
Market Cap

30113.70 K

Enterprise Value

-19312.30 K

ROA (TTM)

-47.14

Very Poor
ROE (TTM)

-55.70

Very Poor
Net Margin (TTM)

-982.87

Very Poor
Revenue

91.87 %

2301.00 K
Net Profit

28.89 %

-38807.00 K
Debt to Equity

0.0242

Excellent
Altman Z Score

-6.04

Very Poor
Quick Ratio

8.01

Excellent
Cash Ratio

7.93

Excellent


Highs/Lows of Angion Biomedica Corp
PeriodOld priceStock ReturnS&P 500 ReturnsHighLowHigh DateLow Date
One Week0.8499 17.66 % 2.10 % 1.120.869931-May-2326-May-23
Two Week0.8 25.00 % 3.59 % 1.120.752531-May-2319-May-23
One Month0.67 49.25 % 3.20 % 1.120.6531-May-2302-May-23
Three Month0.6019 66.14 % 6.96 % 1.120.4631-May-2321-Mar-23
Six Months0.82 21.95 % 15.98 % 1.120.4631-May-2321-Mar-23
One year1.63 38.65 % 24.12 % 2.040.4624-Jun-2221-Mar-23
Two year14.89 93.28 % 48.94 % 9.350.4626-Oct-2121-Mar-23


Technical View of Angion Biomedica Corp
RSI

71.81

Mild Bearish
MACD

0.070

Mild Bullish
ADX

32.61

Bullish
Super Trend

0.681

Mild Bullish
Williams %R

-30.64

Neutral
CCI

158.32

Mild Bearish


EMA 5

0.954

Bullish
EMA 15

0.872

Strong Bullish
EMA 50

0.761

Strong Bullish
EMA 100

0.756

Strong Bullish
SMA 100

0.690

Mild Bullish
SMA 200

0.818

Whipsaw
SMA 5 / 20

0.954 / 0.832

Strong Bullish
SMA 15 / 50

0.850 / 0.708

Strong Bullish
SMA 50 / 200

0.708 / 0.818

Mild Bearish




Charts of Angion Biomedica Corp


Returns of Angion Biomedica Corp with Peers
Period / StockANGNAXDXBCLISABS
1 Week17.66%1.59%-0.647%-2.11%
1 Mth49.25%45.12%-17.29%-10.47%
3 Mth66.14%34.74%29.23%-41.12%
6mth21.95%-72.23%83.06%-55.99%
1 Year-38.65%-84.35%-83.58%-62.64%
2 Year-93.28%-85.29%-85.11%-71.98%
5 Years--99.36%-88.34%-
charts-
View All Together in Chart      Inline           Tile

Compare Fundamentals of Angion Biomedica Corp with Peers
Ratio / StockANGNAXDXBCLISABS
PE-1.04-0.275-1.41-0.519
P/B0.577-0.479-3.940.587
ROA-47.14-136.03-231.00-73.83
ROE-55.7000-113.16
Debt To Equity0.0242-1.93-0.0890.0323
Revenue2301.00 K
91.87 % 		12004.00 K
5.87 % 		0
% 		2238.99 K
90.63 %
Net Income-38807.00 K
28.89 % 		-63229.00 K
1.18 % 		-16632.00 K
31.49 % 		-27211.62 K
45.20 %


Technicals of Angion Biomedica Corp with Peers
Technical / StockANGNAXDXBCLISABS-
ADX32.6129.3222.3724.81
CMF-0.2740.287-0.2200.0310
MFI73.1954.3065.5283.93
RSI71.8156.7043.3549.19
MACD Abv SignalTrueFalseFalseTrue
Price Above 50 MATrueTrueFalseFalse-
Price Above 200 MATrueFalseTrueFalse-


About : Angion Biomedica Corp

Address : 51 Charles Lindbergh Boulevard, Uniondale, NY, United States, 11553
Tel : 415 655 4899
URL : https://www.angion.com
Code : ANGN, ISIN : US03476J1079, Exchange : NASDAQ, Country : USA
Fiscal Year End : December
IPO date : 05_Feb_2021
Employee Count : 3

Angion Biomedica Corp., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapeutics for chronic and progressive fibrotic diseases in the United States. The company develops ANG-3070, an oral tyrosine kinase receptor inhibitor for fibrotic diseases in kidney and lung. It also develops ROCK2 inhibitors for fibrotic diseases; CYP11B2, an inhibitor program for aldosterone-related diseases, including resistant hypertension, congestive heart failure, renal fibrosis, and hyperaldosteronism; and CYP26 for the degradation of retinoic acid. Angion Biomedica Corp. was incorporated in 1998 and is based in Uniondale, New York.


Note : All Data Generated at the End of Trading Hours (EOD Data)